Safety and Efficacy Study of Small Interfering RNA Molecule (Cand5) to Treat Diabetic Macular Edema

Completed · Phase 2

Conditions studied: Diabetic Macular Edema

In brief

The purpose of this study is to evaluate the pharmacokinetics, safety and preliminary efficacy of 3 doses of Cand5. Cand5 is a small interfering RNA molecule that selectively silences the mRNA encoding for VEGF. The target population are patients with diabetic macular edema.

Key facts

Study ID

NCT00306904

Run by

OPKO Health, Inc.

People needed

48

Starts

2006-01-01

Expected to finish

2007-12-01

Last updated by the study team

2008-07-25

Who can join

Age: 21 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients must be male or female age 21 or older.
• Patient must sign (and be given) a copy of the written informed consent form.
• Patients must have the diagnosis of diabetes mellitus (type 1 or type 2). Patients with the following will be considered to be sufficient evidence that diabetes is present:
• Current regular use of insulin for the treatment of diabetes mellitus OR
• Current regular use of oral anti-hyperglycemia agents for the treatment of diabetes OR
• Documented diabetes by WHO criteria
• Patients must have ETDRS best corrected visual acuity of 69 to 24 letters (20/40 to 20/320 Snellen Equivalent) in the study eye.
• Patients must have a mean retinal thickness on OCT ≥ 250 microns in the central subfield.

You may not qualify if…

• Patients with a history of chronic renal failure requiring dialysis or kidney transplant.
• A condition that, in the opinion of the investigator, would preclude participation in the study (e.g., unstable medical status including blood pressure and glycemic control), including:
• Patients in poor glycemic control who, within the last 4 months, initiated intensive insulin treatment (a pump or multiple daily injections) or plan to do so in the next 4 months should not be enrolled.
• Patients with HbA1C > 10%OR
• Patients with systolic blood pressure greater than 170 mmHg and/or diastolic blood pressure greater than 100 mmHg (Note: If blood pressure is brought below 170/100 mmHg by anti-hypertensive treatment, patient can become eligible).
• Past panretinal photocoagulation (PRP) for diabetes within 12 weeks of screening or PRP expected to be needed in the next three months in the study eye.
• Focal laser therapy to the retina of the study eye within 12 weeks of screening.
• Any intraocular surgery or ocular laser procedures in the study eye within 12 weeks of screening.
• Participation in an investigational trial within 30 days of study entry that involved treatment with any drug that has not received regulatory approval at the time of study entry.

Where it is running

• Retina Associates of Cleveland — Beechwood, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.